A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04077099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
Study identification
- NCT ID
- NCT04077099
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 231 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 6, 2020
- Primary completion
- Apr 21, 2032
- Completion
- Apr 21, 2032
- Last update posted
- Jun 16, 2026
2020 – 2032
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Withdrawn |
| University of California Irvine Medical Center - Bldg 56, RT81, Rm 241 | Orange | California | 92868 | Completed |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | Completed |
| Moffitt Cancer Center - McKinley Drive | Tampa | Florida | 33612 | Recruiting |
| University of Kentucky, Markey Cancer Center Clinical Research Organization | Lexington | Kentucky | 40536 | Withdrawn |
| DNU_Massachusetts General Hospital_DNU | Boston | Massachusetts | 02114 | Withdrawn |
| Dana Farber Harvard Cancer Center Consortium | Boston | Massachusetts | 02215 | Completed |
| Henry Ford Health System | Detroit | Michigan | 48202 | Withdrawn |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Withdrawn |
| NYU Cancer Institute | New York | New York | 10016 | Withdrawn |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Completed |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Completed |
| Duke Cancer Center | Durham | North Carolina | 27710 | Withdrawn |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | Withdrawn |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | Withdrawn |
| University of Pittsburgh UPMC - Clinical Research Services | Pittsburgh | Pennsylvania | 15232 | Completed |
| Harold C. Simmons Comprehensive Cancer Center | Dallas | Texas | 75235 | Withdrawn |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04077099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04077099 live on ClinicalTrials.gov.